Paul Ehrlich Institute

Business • Health Care
Pfizer and BioNTech Covid-19 vaccine gets approved for second trial

Pfizer and BioNTech's Covid-19 vaccine BNT162b2 has been approved for its Phase II/III clinical trial by German Paul-Ehrlich-Institut. If the trials prove successful, Pfizer and BioNTech will try to seek regulatory approval as early as October.

"A large, controlled Phase III study is a crucial prerequisite to prove the safety and efficacy of a vaccine. The integration of sites in Europe, and now especially in Germany, is aimed at supporting an approval in Europe," so BioNTech CEO and co-founder Ugur Sahin.